Fresh off two FDA green lights — a full ap­proval for Alzheimer’s and an ac­cel­er­at­ed nod in ALS — Bio­gen CEO Chris Viehbach­er is bring­ing down the bud­get axe and will shrink head­count by about 1,000 by 2025.
Bio­gen is im­ple­ment­ing a ma­jor ex­pand­ed re­duc­tion plan, hop­ing to save $700 mil­lion in net op­er­at­ing ex­pens­es by 2025. An­oth­er $300 mil­lion is…